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Abstract
Severe pulmonary hypertension is a lethal group of
disorders which preferentially afflicts women. It appears that in recent years the patient profile has shifted
towards older, obese, and postmenopausal women,
suggesting that endocrine factors may be important.
Several studies have revealed an increased prevalence
of thyroid disease in these patients, but no studies
have evaluated for a coexistence of endocrine factors.
In particular, no studies have attempted to evaluate for
concurrent thyroid disease, obesity and long-term estrogen exposure in patients.
88 patients attending the Pulmonary Hypertension
Association 8th International meeting completed a
questionnaire and were interviewed. Information was
collected regarding reproductive history, height,
weight, and previous diagnosis of thyroid disease.
46% met criteria for obesity. 41% reported a diagnosis of thyroid disease. 81% of women reported
prior use of hormone therapy. 70% reported greater
than 10 years of exogenous hormone use. 74% of female patients reported two or more of potentially disease modifying endocrine factors (obesity, thyroid disease or estrogen therapy).
The coexistent high prevalence in our cohort of
exogenous estrogen exposure, thyroid disease and
obesity suggests that an interaction of multiple endocrine factors might contribute to the pathogenesis of
pulmonary hypertension and may represent epigenetic
modifiers in genetically-susceptible individuals.

Key words: Severe pulmonary hypertension, Estrogen,
Menopause, Thyroid Disease, Autoimmunity, Obesity

INTRODUCTION

Severe pulmonary arterial hypertension continues to
be categorized as idiopathic pulmonary arterial hypertension (IPAH) or secondary pulmonary hypertension
associated with various disease states (APAH). The
WHO pulmonary hypertension classification system
includes categories of pulmonary arterial hypertension
(PAH), pulmonary hypertension attributable to chronic left heart, lung or thromboembolic disease and
“miscellaneous” forms [1]. Whereas thirty years ago
idiopathic or then called “primary” pulmonary hypertension was recognized as a disease of young women
[2] and the NIH-sponsored pulmonary hypertension

registry reported a female to male ratio of 1.7 : 1 [3], it
appears that in recent years the patient profile has
changed. The average patient diagnosed with IPAH is
now older and frequently, a postmenopausal woman.
The overall number of female patients also appears to
have increased or is potentially overrepresented in
clinical trials [4]. Data from the 2007 REVEAL registry report that 78% of 1226 patients with PAH were
women with a median age of 53 years [5] and a large
referral center reported on 657 patients with PAH, of
which 77% were women and the mean age was 54
years [6]. In 2006, Taraseviciute published a retrospective medical record analysis of 1367 patients with severe PAH which revealed that 541 of these patients
were postmenopausal women and that 217 of the
women had a BMI >30kg/m2 [7]. The discovery of
the familial IPAH gene, BMPRII [8] and of the association of ALK-1 gene mutations in patients with
hereditary hemorrhagic telangiectasia (HHT) and PAH
[9] provide the solid foundation for the concept of a
genetic PAH predisposition. It has, however, been recognized that only about 50% of patients with germline BMPRII mutation develop severe PAH [10] and
that the incidence of PAH in groups of patients with
acknowledged risk factors, such as HIV infection or
anorexigen drug intake, is low [11-12]. Remarkably,
even in patients with significant intra-cardiac shunt,
the fraction of patients who develop PAH is small.
This raises the question whether there are additional
previously unrecognized factors which, in concert with
known trigger factors, can modify the risk of PAH development.
The shift in the patient profile towards older, obese,
and postmenopausal women led us to postulate that
there may be two previously unrecognized endocrine
factors, which, when added to the genetic PAH susceptibility, may not only increase the risk of PAH development but also may be pathobiologically important.
These factors include obesity, now recognized as a state
of systemic inflammation [13] and exposure to potentially angiogenic estrogens in the form of hormone
therapy for contraception or management of menopause. The concept of endocrine modulators in PAH is
not entirely new. For example, several studies have reported an increased prevalence of autoimmune thyroid
disease in PAH patients as compared to population
based studies [14]. As autoimmunity, inflammation and
angiogenesis [15-16] may each contribute to the patho-
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genesis of severe PAH, we developed a questionnaire
and conducted an interview in order to obtain information regarding these putative endocrine risk factors in
patient volunteers assembled at the 2008 biannual
meeting of the Pulmonary Hypertension Association.
In particular, information regarding reproductive history, thyroid disease, height and weight was obtained. In
the design of the questionnaire we were guided by epidemiological studies in hormone responsive cancers
conceived to shed light on possible associations between reproductive history and cancer development
[17]. Here we present data which suggest that obesity,
hormone therapy and thyroid disease are frequent findings in this group of patients with severe PAH.

METHODS

STUDY POPULATION

Patients attending the Pulmonary Hypertension Association 8th International Pulmonary Hypertension
Conference and Scientific Sessions (Houston, TX)
were recruited for enrollment in the study. This conference is a forum for interactions between PH patients, motivated to learn about their disease, and PH
clinicians and researchers. In recent years the conference has provided a “research room” for the purposes
of recruitment of PH patients and to facilitate the collection of blood and clinical samples. Patients were
considered eligible for our study if they reported a diagnosis of pulmonary hypertension, were currently receiving medical treatment for PAH and were able to
give informed consent. IRB approval was obtained
prior to the initiation of this study.
MEDICAL HISTORY

Questions regarding the medical history included: current age, height, weight, age at diagnosis of PH, and
current medications (in particular the use of prostacyclin or prostacyclin analogues). Patients were also
asked about the “likely cause” of their pulmonary hypertension as it had been explained to them by their
physician. Patients were also asked whether they had
known family members with PH and to report the
gender of these pulmonary hypertension patient relatives.
BASELINE SURVEY

Informed consent was obtained from each participant
before study enrollment. A self-administered questionnaire which included the pertinent history regarding
diagnosis and treatment of PH, current medications,
family history of PH, reproductive history and history
of thyroid disease was distributed to all consented patients. Completed questionnaires were collected within
2 subsequent days from 89 patients.
PATIENT INTERVIEW

A standardized interview was conducted by a
board-certified endocrinologist for the purpose of allowing the patients to ask questions and for further
explanation of their written responses. All interviews
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were conducted by L.B.S.; and the average length of
the interview was 10 minutes.
REPRODUCTIVE FACTORS AND HORMONE USE

Questions regarding reproductive factors included age
at menarche, menstruation status, regularity of menstruation, length of menstruation, history of hysterectomy/oopherectomy, history of infertility (inability to become pregnant despite attempts greater
than 1 year), history of polycystic ovarian syndrome
(PCOS), history of pregnancy and live birth, history
and length of breastfeeding, type of menopause (natural or induced) and history of exogenous estrogen
exposure (female hormone treatment and ingestion of
phyto-estrogens). Information collected on hormone
treatment included current or past use of contraceptive agents (oral, transdermal, injection, and IUD) and
agents initiated for menopause symptoms (oral preparation, transdermal preparation, vaginal estrogen
cream). No questions were asked regarding dose
or composition (estrogen/progestin) of hormone
therapy given the anticipated difficulty in patient recall
for these details [18]. Patients were instructed, however, to estimate the total duration of therapy for
each agent. Patients were also asked about their personal history of hormone responsive cancers (breast
or ovarian cancer) and history of anti-estrogen
therapy.
LIFELONG ESTROGEN EXPOSURE

There is growing evidence to support the role of endogenous estrogens in the development of certain
hormone responsive cancers [19]. Greater lifelong exposure to ovarian estrogen as occurs with early menarche, null parity and late menopause is associated with
increased risk for the development of breast, endometrial and ovarian cancer in premenopausal women [20].
In postmenopausal women higher circulating estrogen
levels are observed in obesity and these factors may
act synergistically to confer increased risk in the development of hormone responsive cancer [21]. Although
the risk of breast cancer associated with exogenous estrogen is somewhat controversial, current evidence
suggests that prolonged estrogen therapy increases the
risk of breast cancer, especially among younger
women (age <25 years) [22].
There has been recent interest in the relationship
between hormone responsive cancer and soy-derived
isoflavone ingestion. Soyfoods (isoflavones) have estrogen-like properties under certain conditions and
may stimulate the growth of estrogen sensitive breast
tumors [23]. Many women incorporate soyfoods into
their diets to attenuate vasomotor symptoms of
menopause [24].
In an effort to quantify cumulative lifelong endogenous and exogenous estrogen exposure, we evaluated
subjects according to several major epidemiologic risk
factors which have been previously identified in studies of hormone responsive cancers. These include
obesity, parity, total years of menstruation, use exogenous female hormones, history of ovarian or breast
cancer, and ingestion of soy isoflavones. Based on
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CHARACTERISTICS OF THE COHORT

Table 2 shows the baseline information and distribution of characteristics in the cohort. The total number
of subjects was 88. 89% of subjects were female. The
mean age of the cohort was 50.4 years. The mean age
at diagnosis of PH was 44.2 years. A high rate of obesity was observed as the mean BMI was 31.7 kg/m2.
56% of participants reported having primary (familial
or idiopathic) pulmonary hypertension. Individuals reporting PH associated with various diseases included
the following: 21 patients with collagen vascular disease (RA, scleroderma, CREST), 5 patients with OSA,
6 patients with congenital or acquired cardiac disease
(systemic to pulmonary shunt, valvular disease), 1 patient with portal hypertension, 1 patient with COPD, 1
patient with HIV and 1 patient with chronic thromboembolic disease. Lastly, 3 individuals reported
anorexigen related PH. PH treatment included prostacyclin therapy in 37, endothelin receptor antagonists in
39, and PDE-5 inhibitors in 46 and calcium channel
blockers in 10 patients. 48 subjects were on multiple
drug therapy.

these factors we generated an arbitrary scoring system
to characterize the extent and contribution of each element to the overall long-term estrogen exposure.
Table 1 shows the elements of this scoring system.
The total number of possible points for each subject
was 12.

Table 2.

THYROID DISEASE

Participant PH patients were asked whether they had
ever been diagnosed with thyroid disease and whether
they had ever been on thyroid replacement therapy.
During the patient interview, the interviewer asked
further questions to clarify the type of thyroid disease
(hypothyroidism, hyperthyroidism, thyroid cancer) reported by participants and to clarify whether the disorder required medical therapy (drug therapy, surgery or
radioactive iodine). The form of thyroid disease and
the treatment, if any, was recorded.
OBESITY

Participants were asked to record their height and
weight as measured most recently at their physician’s
office. BMI was calculated from self-report of height
and weight.
ROLE OF THE FUNDING SOURCE

This work has been supported by the following research grants to L.B.S.: Thomas F. Jeffress and Kate
Miller Jeffress Memorial Trust research grant and
VCU Health System BIRCWH award. Neither funding
source was involved in the study design, collection or
analysis of data, manuscript preparation or decision to
submit the manuscript for publication.

REPRODUCTIVE FACTORS

For decades there has been considerable interest in the
female predominance of pulmonary hypertension.
This has generated important questions regarding the
potential for endogenous and exogenous estrogens to
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underlie the observed sex differences. Table 3 shows
selective reproductive history characteristics of the female patients in the cohort.
EXOGENOUS ESTROGEN EXPOSURE

A significant proportion of female PH patients reported prior use of exogenous estrogens. 69% of premenopausal females reported prior use of oral contraceptive pills (OCP), and 1 subject reported current
use. 92% of postmenopausal women reported prior
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use of OCP and 67% reported prior use of estrogens
in the form of hormone replacement therapy (HRT)
following spontaneous or induced menopause. 3 subjects reported current use of HRT. These rates exceed
estimates of OCP and HRT usage as compared to
data derived from NHANES [25-26]. In the premenopausal subgroup, 45% the reported less than 10
yrs of OCP use, whereas 56% of postmenopausal
women reported greater than 10 years of exogenous
estrogen use. 2 subjects reported greater than 15 years
and 7 subjects reported greater than 20 years of estro-
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gen exposure. While specific data was not collected regarding the timing of estrogen therapy relative to diagnosis of PH, the mean age of the entire cohort was
50.4 years and the mean age at diagnosis was 44.2
years. As a majority of subjects in the postmenopausal
group reported greater than 10 years of estrogen exposure, it is very likely that exogenous estrogen exposure occurred prior to diagnosis of pulmonary hypertension in this group. Among females reporting diagnosis of PH prior to 40 years of age, 75% also reported prior use of OCP.
LIFELONG ESTROGEN EXPOSURE

In an effort to roughly quantify lifelong estrogen exposure (load) we evaluated female PAH patients with
regards to several major epidemiologic risk factors
(some conferring increased risk and others conferring
protection) which have been identified in studies of
hormone responsive cancers. These included obesity,
parity, total years of menstruation, exogenous
hormone usage, history of ovarian or breast cancer,
history of prolonged breast feeding, and ingestion
of soy isoflavones. Collectively these factors were
used to generate point system which was applied to
each subject. Figure 1 depicts the proportion of risk
factors points reported by subjects according to their
menopause status. This assessment of reproductive
history revealed that only 16% of premenopausal
females reported none of these reproductive risk
factors. A large proportion of these patients had
either familial PAH or PAH associated with collagen
vascular disease. With regards to the existence of
multiple risk factor points, 29% of the premenopausal and 46% of postmenopausal women reported
greater than 4 risk factors points. Regarding estrogen
responsive cancers in the subgroup, 5 women reported breast cancer treated with anti-estrogen therapy.
Of 3 subjects reporting DVT, all had used OCP and
one individual had a concurrent history of breast
cancer.
PREVALENCE OF THYROID DISEASE

For the purposes of our study, thyroid disease was defined as “overt” hypo or hyperthyroidism requiring
therapy or thyroid cancer. Several subjects reported a
history of benign nodular thyroid disease or subclinical hypothyroidism, but these were not included for
analysis. Table 2 shows the distribution of thyroid disease per self-report. The prevalence of self-reported
thyroid disease in our cohort was 41%. While previous
Premenopausal Females
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studies have reported as much as three-fold increase in
prevalence of thyroid disease in PAH patients [27],
our cohort reported thyroid disease at a rate six times
that of large population based estimates of thyroid
disease [28].
The percentage of subjects reporting thyroid disease was as follows: 84% of patients with thyroid disease reported having hypothyroidism, 8% reported
having hyperthyroidism and 8% reported a history of
thyroid cancer. The highest prevalence of thyroid disease was reported by patients aged 60-69 years and the
lowest prevalence was reported by those aged 20-29
years. Although no discrete pattern emerged, there
was a trend towards an age related increase in prevalence of thyroid disease. Controversy currently exists
regarding the potential for prostacyclin therapy to induce or “unmask” thyroid disease [29]. The largest
proportion of patients reporting both thyroid disease
and current prostacyclin therapy occurred in the 30-39
year old group. This may explain the higher than expected prevalence of thyroid disease in this relatively
young subgroup.
THYROID DISEASE ACCORDING TO PH SUBTYPE

41% of patients with “secondary” PH reported thyroid disease as compared to 38% of patients with primary disease. Nearly 50% of patients with “secondary” PAH and thyroid disease had collagen vascular disease (CREST syndrome, RA, scleroderma)
which might reflect enhanced susceptibility to autoimmune disorders in these individuals. Several studies
have reported associations between subclinical or
overt thyroid disease and sleep disordered breathing
[30]. Among individuals in our cohort with pulmonary
hypertension secondary to OSA, 75% reported thyroid disease. The mean BMI of this group was 45.9
kg/m2. All individuals with OSA reported a diagnosis
of hypothyroidism and current treatment with thyroid
replacement hormone.
PREVALENCE OF OBESITY

The mean BMI of the entire cohort was 31.7 kg/m2.
46% of patients met criteria for obesity as defined by
a BMI > 30 kg/m2 (Fig. 2). The prevalence of obesity
was the most pronounced in the 50-59 year old subgroup, followed closely by the 40-49 year old subgroup. The rate of obesity in our cohort exceeds the
prevalence of obesity as suggested by NHANES data
[31]. 13 subjects were currently on glucocorticoid
therapy.

Postmenopausal Females

Fig. 1. Reproductive risk factor
point distribution for the cohort
is shown according to menopause status.
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Fig. 2. Distribution of these risk factors and the combination
of risk factors.

PREVALENCE OF MULTIPLE ENDOCRINE RISK FACTORS

We analyzed all females in the cohort for the presence
of multiple endocrine risk factors to include BMI >30
kg/m 2, previous use of exogenous estrogens and thyroid disease requiring medical therapy. Figure 3 depicts
the results. Nine percent of females had no risk factor
points and 17% had one risk factor point. 74% of patients had multiple endocrine factors points and this
group was comprised mostly of postmenopausal females (Fig. 2).

DISCUSSION

Apparently during the last 20 years more patients in
the U.S.A. have received the diagnosis of pulmonary
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hypertension than in preceding decades [32]. Overall,
severe PAH is a group of rare diseases, either idiopathic or associated with known causes. Whereas
progress has been made to elucidate the gene mutations which underlie the susceptibility for PAH development in some groups of patients [33] little is known
about modifiers of disease or epigenetically important
factors and conditions. One of several disease modifiers may be female gender as a greater prevalence of
women in all forms of PAH has been recognized for
decades [2]. It is remarkable that the fraction of
women, and in particular older women, in most
groups of PAH patients has increased in recent years
and also that no hypothesis for this gender preference
has been developed. Although a causative or permissive role of angiogenic and perhaps proinflammatory
estrogen metabolites [34] is now somewhat intuitive,
there are no data on cumulative life-long estrogen exposure in PH patients. Another risk factor for development of PAH is autoimmunity [35]. All forms of
autoimmune disorders are more prevalent in women
and hormonal factors have been considered to explain
this prevalence. Increased rates of autoimmune thyroid disease have been observed in patients with IPAH
and many disease-associated forms of pulmonary hypertension [36]. Lastly obesity, now recognized as a
complex endocrinopathy with a systemic inflammatory
component and a risk factor for hormone-sensitive
cancers [37], has recently been reported in women
with PAH [7].
In order to survey the prevalence of these individual factors and conditions in a cohort of patients with
the diagnosis of severe PAH, both a focused endocrine disorder questionnaire was administered and
an interview was conducted. Here we report a high
prevalence of long-term estrogen exposure, thyroid
disorder and obesity in this cohort of PAH patients.
As the overwhelming number of patients in this cohort were women, we focus the following discussion
on the female patients’ characterization.

Autoreactive CD4
T cells

Fig. 3. Schematic illustrating the potential interactions of pathobiologically
relevant risk factos which may contribute to severe angioproliferative pulmonary arterial hypertension. Hypothetically, autoimmunity and chronic
inflammation interact via thyroid disease, estrogen and obesity.
VEGF = vascular endothelial growth
factor, Bcl-2 = antiapoptotic B-cell
lymphoma protein
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LONG-TERM ESTROGEN EXPOSURE

Early and long term estrogen exposure has been correlated with an increased risk for the development of
hormone responsive cancers. There is also accumulating evidence that estrogen is a key regulator of endothelial cell proliferation and function in vivo [38].
Similar mechanisms which underlie both carcinogenesis and endothelial cell proliferation include estrogen
induced VEGF expression, decreased synthesis of
proteins required for apoptosis and up-regulation of
protective genes in cell death pathways [39]. Given our
current understanding of the pathology of PAH
which includes the phenotype switch of pulmonary
vascular endothelium into a highly proliferative, apoptosis-resistant phenotype [40], we have a growing interest in estrogen exposure in the context of PAH. As
such, we were particularly impressed with the rates of
self-reported hormone therapy in our cohort. Indeed
71% of the premenopausal and 86% of the postmenopausal women reported previous or current use
of hormone therapy. In the postmenopausal subgroup, more than 50% of patients reported greater
than 10 years of hormone therapy, which was most
commonly a prolonged use of oral contraceptive pills.
While we intentionally avoided questions regarding
hormone dose and estrogen/progestin composition,
the OCP preparations commonly prescribed to
women of a similar age as our post-menopausal subgroup consisted of higher dose estrogen than is commonly prescribed today [41]. This prominent use of
hormone therapy was reflected in our scoring of lifelong estrogen exposure in our cohort. In fact, in postmenopausal patients, obesity and prolonged hormone
therapy were the most significant contributors to our
putative risk factor score. Of interest, is the observation that only a small proportion of women had no
risk factors. These were young women (average age
<22 years) with either familial IPAH or PAH associated with CREST syndrome. Perhaps in these individual
women, genetic or disease associated factors are
prominent enough to promote the development of
PAH, and the contribution of a “second hit” is less
important. It may also be of interest that the use of
phytoestrogens was common in this patient cohort.
AUTOIMMUNE THYROID DISEASE

It has been established that a higher prevalence of autoimmune thyroid disease exists in PH patients, and
that anti-thyroid antibodies can be detected in patients
without overt thyroid dysfunction at rates higher than
the general population [40]. Thyrotoxicosis has also
been considered a risk factor for pulmonary arterial
hypertension, and treatment with thionamides in this
population can reverse PAH [43-44]. We found a high
proportion of patients in our cohort reporting a history of thyroid disease and current use of thyroid hormone supplementation. Indeed thyroid disease among
our patients was prevalent at a rate nearly double that
recently published by Burger and colleagues at Mayo
Clinic [45]. In their retrospective study thyroid disease
was defined as abnormal TSH, history of thyroid disease on replacement or elevated TPO antibody. While
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we did rely on self-report of thyroid disease in our
study, we defined individuals as having thyroid dysfunction only if they required medical therapy. Of
course we do not have information on the severity of
thyroid gland dysfunction at the time of initiation of
therapy, so it is possible that some patients were currently on therapy for subclinical thyroid disease.
The majority of patients reporting thyroid disease
were hypothyroid and a significant proportion also reported current therapy with prostacyclin or prostacyclin analogs. There has been a longstanding interest in
the potential of prostacyclin to induce thyroid disease
in PAH patients [46]. Indeed thyroid tissue has high
and low affinity receptors for prostacyclin and alterations in receptor density and kinetics have been observed in Hashimoto’s, Reidel thyroiditis, autonomous
thyroid nodules and thyroid cancer [47]. Prostacyclin
infusion can also enhance TSH secretion and promote
peripheral conversion of T4 to T3 [48]. Currently
there is no consensus regarding the importance of establishing baseline thyroid function in patients with
PAH, nor in monitoring thyroid function prior to or
after the initiation of prostacyclin therapy. Additionally, there have been no studies to date which have evaluated the treatment of subclinical thyroid dysfunction
in this population. Treatment of thyroid dysfunction
in PAH may have important pathobiological consequences. While the effects of thyroid hormone on
lung ventilation/oxygenation and peripheral vascular
resistance [49] have been characterized for some time,
new evidence suggests that thyroid hormone through
non-genomic signaling may induce proliferation and
promote migration of human arterial smooth muscle
cells [50].
OBESITY

The high prevalence of obesity in our cohort echoes
recent findings from larger PH surveys and may be
important in the pathobiology of PH. It is now recognized that obesity is a systemic process characterized
by chronic inflammation, pro-angiogenesis and impaired immune function [51]. Adipose tissue is a dynamic organ capable of synthesis and secretion of
proinflammatory cytokines, hormones (adipokines)
and potent growth factors which have local paracrine
and systemic effects [52]. The accumulation of intraabdominal fat leads to impaired insulin signaling, and
decreased intracellular glucose transport [53]. These
signaling defects result in impaired endothelium-dependent vasodilation [54]. Additionally, obesity is associated with characteristic changes in the proportion of
adipose derived hormones. Fat-pad production of
adiponectin and ghrelin is decreased, and the production of leptin is increased with caloric excess [55].
While these hormones have well established roles in
energy homeostasis, current research also suggests
that they may be important regulators of angiogenesis
[56]. Adiponectin has been shown to inhibit tumor cell
proliferation, microvessel angiogenesis and VEGF-induced migration of coronary artery endothelial cells
[57]. Conversely, leptin is mitogenic to vascular endothelium and and coronary artery smooth muscle
cells, likely through upregulation of VEFGR-1 [58].
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Leptin also induces matrix remodeling through upregulation of matrix metalloproteinases [59]. Our understanding of the relationship between obesity and innate immunity now extends beyond the concept of
chronic inflammation resulting in immune dysfunction
(Fig. 3). The fat pad is a reservoir for macrophages
which are functionally similar to “M1” or classically
activated macrophages [60], and the immunodeficiency
of obesity involves defective T-cell to mitogen response, and decreased NK cell activity [61]. There are
also overlapping defects in key signaling pathways in
obesity and PH. It is intriguing that TGF-β signaling is
impaired in PH and that proper signaling through this
pathway is key to the regulation of satiety in humans
(through DAF-7) [62]. This has interesting implications regarding potential therapies targeted to both
PH and obesity.
As investigators are beginning to consider PAH disease modifiers, each of these putative factors or conditions present in our cohort could indeed represent an
initiating or disease modifying factor. Although the rationale for hypothetically linking long-term estrogen
exposure, autoimmune thyroid disease and obesity
with the development of PAH (Fig. 3) is attractive, our
approach to data gathering and data analysis can provide circumstantial evidence at best. Neither long term
estrogen exposure nor obesity have previously been
considered important risk or trigger factors for PAH.
Abehaim et al. [63] in their prospective case control
study of anorexigen induced PAH could not establish
a statistically significant link between obesity and
PAH, however the cohort studied was European and
obesity is still less prevalent in Europe as compared to
the US population. Overall larger multicenter cohorts
have not been evaluated for the presence or prevalence of these putative risk factors and the concept of
potentially important epigenetic factors in the development of PAH are not generally accepted. It is evident that hypothesis-driven mining of databases requires the inclusion of data which are pertinent to the
subject under investigation and it is therefore regrettable that the recently established REVEAL pulmonary hypertension data bank does not contain elements of the reproductive history of women. As there
is presently no general acceptance of a concept of
epigenetic modifiers, there is certainly no appreciation
for a potential confluence or interaction of multiple
(at present putative) factors. Indeed the data derived
from our questionnaire and interview document that
the majority of the PAH patients presented with more
than one of these putative risk factors, in fact, nearly
three-quarters of these patients presented with more
than one of these factors.
LIMITATIONS

Clearly, like any relatively small cohort study, ours has
a number of limitations and the results are in some
danger of over-interpretation. We chose to investigate
patients attending the 2008 International Pulmonary
Hypertension Association meeting and these individuals represent a subset highly motivated to participate
in clinical studies. As such, our findings might not be
generalizable to larger groups of PAH patients. Addi-

September 28, 2009

tionally, many patients were from specialized PAH
treatment centers in the US. It could be argued that
this group likely has enhanced access to medical care
such that surveillance for and diagnosis of thyroid disease could have been increased. Second, our study design included a self-administered questionnaire and
personal interview and relied largely upon recall of
clinical data, and as such, was subject to recall bias.
Previous studies which have compared recalled and
validated elements of the reproductive history have
shown fair to excellent agreement in personal recall of
onset and duration of menses, parity, and use of hormone therapy. Less agreement has been observed in
recall of hormone preparation, duration of hormone
therapy and onset of menopause [64-65]. Also, as we
relied upon self-report of most recent height and
weight when calculating BMI, our results likely represent an underestimation of true BMI. Several studies
suggest that self-reported weight can vary by as much
as 3 kilograms from measured weight and that in most
cases it is underestimated [66]. Lastly, as some of our
questions could be considered sensitive, and the patient interview was conducted by a single board-certified endocrinologist, the potential exists for both interviewer and respondent bias to have influenced our
results. Furthermore, the questionnaire used here has
not been previously validated in the form presented to
these PAH patients, although the composition of the
questions is similar to those commonly used in the
field of hormone-sensitive cancer epidemiology. Our
decision to use an arbitrary point score system in order to attempt a more quantitative assessment of estrogen exposure was entirely ours and may be subject
to severe criticism. Finally, we need to emphasize that
our process of data gathering amounts to little more
than a first survey of a potentially very complex interplay between genetic and endocrine risk factors in female patients with PAH. Nevertheless, the results of
our survey can be seen as hypothesis-generating and
may provide the basis for the design of a prospective
multi-center study of women with PAH which would
focus on these putative risk factors. Such a study
would rely upon a questionnaire similar to ours and
would for its analysis not rely upon comparative data
derived from existing databases.
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